Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) EPS (Basic) (2021 - 2025)

Aligos Therapeutics filings provide 5 years of EPS (Basic) readings, the most recent being -$2.01 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 84.66% to -$2.01 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.46, a 93.03% increase, with the full-year FY2025 number at -$2.45, up 88.3% from a year prior.
  • EPS (Basic) hit -$2.01 in Q4 2025 for Aligos Therapeutics, up from -$3.04 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $5.12 in Q1 2025 to a low of -$13.1 in Q4 2024.
  • Median EPS (Basic) over the past 5 years was -$0.78 (2021), compared with a mean of -$1.94.
  • The widest YoY moves for EPS (Basic): up 288.37% in 2024, down 3458.97% in 2024.
  • Aligos Therapeutics' EPS (Basic) stood at -$0.91 in 2021, then skyrocketed by 43.96% to -$0.51 in 2022, then skyrocketed by 176.47% to $0.39 in 2023, then crashed by 3458.97% to -$13.1 in 2024, then skyrocketed by 84.66% to -$2.01 in 2025.
  • The last three reported values for EPS (Basic) were -$2.01 (Q4 2025), -$3.04 (Q3 2025), and -$1.53 (Q2 2025) per Business Quant data.